These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 29538767)

  • 1. A new class of antibacterials, the imidazopyrazinones, reveal structural transitions involved in DNA gyrase poisoning and mechanisms of resistance.
    Germe T; Vörös J; Jeannot F; Taillier T; Stavenger RA; Bacqué E; Maxwell A; Bax BD
    Nucleic Acids Res; 2018 May; 46(8):4114-4128. PubMed ID: 29538767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding.
    Mustaev A; Malik M; Zhao X; Kurepina N; Luan G; Oppegard LM; Hiasa H; Marks KR; Kerns RJ; Berger JM; Drlica K
    J Biol Chem; 2014 May; 289(18):12300-12. PubMed ID: 24497635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA Topoisomerase Inhibitors: Trapping a DNA-Cleaving Machine in Motion.
    Bax BD; Murshudov G; Maxwell A; Germe T
    J Mol Biol; 2019 Aug; 431(18):3427-3449. PubMed ID: 31301408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin.
    Chan PF; Srikannathasan V; Huang J; Cui H; Fosberry AP; Gu M; Hann MM; Hibbs M; Homes P; Ingraham K; Pizzollo J; Shen C; Shillings AJ; Spitzfaden CE; Tanner R; Theobald AJ; Stavenger RA; Bax BD; Gwynn MN
    Nat Commun; 2015 Dec; 6():10048. PubMed ID: 26640131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type IIA topoisomerase inhibition by a new class of antibacterial agents.
    Bax BD; Chan PF; Eggleston DS; Fosberry A; Gentry DR; Gorrec F; Giordano I; Hann MM; Hennessy A; Hibbs M; Huang J; Jones E; Jones J; Brown KK; Lewis CJ; May EW; Saunders MR; Singh O; Spitzfaden CE; Shen C; Shillings A; Theobald AJ; Wohlkonig A; Pearson ND; Gwynn MN
    Nature; 2010 Aug; 466(7309):935-40. PubMed ID: 20686482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiophene antibacterials that allosterically stabilize DNA-cleavage complexes with DNA gyrase.
    Chan PF; Germe T; Bax BD; Huang J; Thalji RK; Bacqué E; Checchia A; Chen D; Cui H; Ding X; Ingraham K; McCloskey L; Raha K; Srikannathasan V; Maxwell A; Stavenger RA
    Proc Natl Acad Sci U S A; 2017 May; 114(22):E4492-E4500. PubMed ID: 28507124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bimodal Actions of a Naphthyridone/Aminopiperidine-Based Antibacterial That Targets Gyrase and Topoisomerase IV.
    Gibson EG; Oviatt AA; Cacho M; Neuman KC; Chan PF; Osheroff N
    Biochemistry; 2019 Nov; 58(44):4447-4455. PubMed ID: 31617352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase.
    Gibson EG; Bax B; Chan PF; Osheroff N
    ACS Infect Dis; 2019 Apr; 5(4):570-581. PubMed ID: 30757898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones.
    Malik M; Mustaev A; Schwanz HA; Luan G; Shah N; Oppegard LM; de Souza EC; Hiasa H; Zhao X; Kerns RJ; Drlica K
    Nucleic Acids Res; 2016 Apr; 44(7):3304-16. PubMed ID: 26984528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Dynamics Simulations of Quinolone Resistance-Associated T86I and P104S Mutations in Campylobacter jejuni gyrA: Unraveling Structural Repercussions.
    Mehla K; Ramana J
    Microb Drug Resist; 2018 Apr; 24(3):232-243. PubMed ID: 28759328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the Water-Metal Ion Bridge in Quinolone Interactions with
    Carter HE; Wildman B; Schwanz HA; Kerns RJ; Aldred KJ
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hot-spot consensus of fluoroquinolone-mediated DNA cleavage by Gram-negative and Gram-positive type II DNA topoisomerases.
    Richter SN; Giaretta G; Comuzzi V; Leo E; Mitchenall LA; Fisher LM; Maxwell A; Palumbo M
    Nucleic Acids Res; 2007; 35(18):6075-85. PubMed ID: 17766248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents.
    Tari LW; Li X; Trzoss M; Bensen DC; Chen Z; Lam T; Zhang J; Lee SJ; Hough G; Phillipson D; Akers-Rodriguez S; Cunningham ML; Kwan BP; Nelson KJ; Castellano A; Locke JB; Brown-Driver V; Murphy TM; Ong VS; Pillar CM; Shinabarger DL; Nix J; Lightstone FC; Wong SE; Nguyen TB; Shaw KJ; Finn J
    PLoS One; 2013; 8(12):e84409. PubMed ID: 24386374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional Characterization of the DNA Gyrases in Fluoroquinolone-Resistant Mutants of Francisella novicida.
    Caspar Y; Siebert C; Sutera V; Villers C; Aubry A; Mayer C; Maurin M; Renesto P
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.
    Kern G; Palmer T; Ehmann DE; Shapiro AB; Andrews B; Basarab GS; Doig P; Fan J; Gao N; Mills SD; Mueller J; Sriram S; Thresher J; Walkup GK
    J Biol Chem; 2015 Aug; 290(34):20984-20994. PubMed ID: 26149691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 2.8 Å Structure of Zoliflodacin in a DNA Cleavage Complex with
    Morgan H; Lipka-Lloyd M; Warren AJ; Hughes N; Holmes J; Burton NP; Mahenthiralingam E; Bax BD
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent DNA gyrase inhibitors bind asymmetrically to their target using symmetrical bifurcated halogen bonds.
    Kolarič A; Germe T; Hrast M; Stevenson CEM; Lawson DM; Burton NP; Vörös J; Maxwell A; Minovski N; Anderluh M
    Nat Commun; 2021 Jan; 12(1):150. PubMed ID: 33420011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual Escherichia coli DNA Gyrase A and B Inhibitors with Antibacterial Activity.
    Fois B; Skok Ž; Tomašič T; Ilaš J; Zidar N; Zega A; Peterlin Mašič L; Szili P; Draskovits G; Nyerges Á; Pál C; Kikelj D
    ChemMedChem; 2020 Feb; 15(3):265-269. PubMed ID: 31721445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and Optimization of DNA Gyrase and Topoisomerase IV Inhibitors with Potent Activity against Fluoroquinolone-Resistant Gram-Positive Bacteria.
    Lapointe G; Skepper CK; Holder LM; Armstrong D; Bellamacina C; Blais J; Bussiere D; Bian J; Cepura C; Chan H; Dean CR; De Pascale G; Dhumale B; Fisher LM; Fulsunder M; Kantariya B; Kim J; King S; Kossy L; Kulkarni U; Lakshman J; Leeds JA; Ling X; Lvov A; Ma S; Malekar S; McKenney D; Mergo W; Metzger L; Mhaske K; Moser HE; Mostafavi M; Namballa S; Noeske J; Osborne C; Patel A; Patel D; Patel T; Piechon P; Polyakov V; Prajapati K; Prosen KR; Reck F; Richie DL; Sanderson MR; Satasia S; Savani B; Selvarajah J; Sethuraman V; Shu W; Tashiro K; Thompson KV; Vaarla K; Vala L; Veselkov DA; Vo J; Vora B; Wagner T; Wedel L; Williams SL; Yendluri S; Yue Q; Yifru A; Zhang Y; Rivkin A
    J Med Chem; 2021 May; 64(9):6329-6357. PubMed ID: 33929852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA gyrase inhibitors: Progress and synthesis of potent compounds as antibacterial agents.
    Khan T; Sankhe K; Suvarna V; Sherje A; Patel K; Dravyakar B
    Biomed Pharmacother; 2018 Jul; 103():923-938. PubMed ID: 29710509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.